GOP Doctors Caucus Endorses Bipartisan Protecting Patient Access to Cancer and Complex Therapies Act

Washington, D.C. - Today, the GOP Doctors Caucus announced its endorsement of H.R. 4299, the Protecting Patient Access to Cancer and Complex Therapies Act, bipartisan legislation to protect Medicare patients’ access to physician-administered Part B medicines.

Beginning in 2028, changes to Medicare reimbursement for certain Part B drugs could threaten patients’ access to critical cancer and complex therapies by making it financially unsustainable for independent physician practices and community-based providers to continue administering these treatments. Without congressional action, patients could be forced to travel farther or seek treatment in higher-cost hospital settings.

H.R. 4299 would protect patient access by maintaining provider reimbursement at ASP + 6 percent while ensuring the Medicare program and Medicare beneficiaries continue to benefit from lower negotiated prices. Manufacturers would rebate the difference to Medicare, preserving the savings generated by the Medicare Drug Price Negotiation Program, while removing providers from the middle of negotiations between CMS and pharmaceutical manufacturers.

“As physicians, we know that lowering prescription drug costs for seniors cannot come at the expense of their ability to access those medicines in the first place,” said GOP Doctors Caucus Co-Chair Congressman Greg Murphy, M.D. “H.R. 4299 provides a commonsense solution that preserves the savings of Medicare drug price negotiation while ensuring physicians are not collateral damage in negotiations between the federal government and drug manufacturers. Patients battling cancer and other serious diseases should be able to receive the treatment they need from the physician they trust and, in the community where they live.”

“H.R. 4299 protects both patients and the physicians who care for them,” said GOP Doctors Caucus Co-Chair Congressman John Joyce, M.D. “Independent providers are already operating under tremendous financial pressure, particularly in rural and underserved communities. We should not allow an unintended reimbursement cut to push more physicians out of independent practice, accelerate consolidation, or force patients into more expensive sites of care. This bipartisan legislation ensures Medicare beneficiaries continue to benefit from lower drug costs while protecting access to high-quality, physician-led care close to home.”